source
- Venture debt becomes central financing option for late-stage European biotechBioSpace’s Denatured podcast recently featured Jennifer McMahon of Seroba and Joey Mason of Claret Capital discussing the growing role of venture debt in European biotech. The guests explained tha…
- Iambic Therapeutics targets $135M IPO to fund clinical trials of HER2 and KIF18A cancer drugsIambic Therapeutics, a San Diego AI‑driven biotech, filed to raise $135 million in net proceeds through an initial public offering. The company plans to sell 9.4 million shares at $15 to $17 each,…